Dr. Ferrer BioPharma

Company snapshot

Who we are: We are the leading innovators in intranasal medications for the treatment of cough, colds, flu, and allergies. We use advanced nanoparticle technology to bring to the market high-quality evidence-based, consumer-focused, and doctors-invented products. OUR MISION: To bring to the market evidence-based therapies combining new ideas with proven concepts in the service of helping people -

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Dr. Ferrer BioPharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Dr. Ferrer BioPharma.

1. Jun 8, 2026 Clinical update

   PRIDOPIDINE, Pridopidine placebo — Phase 3

2. May 26, 2026 Clinical update

   FNP-223, Film coated tabled — Phase 2

View all clinical trial activity →

• What is Dr. Ferrer BioPharma?

  Ferrer Internacional is a pharma organization headquartered in Barcelona, ES. Primary therapeutic focus areas include Progressive supranuclear palsy (PSP), Amyotrophic Lateral Sclerosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this

• Is Dr. Ferrer BioPharma publicly traded?

  Dr. Ferrer BioPharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Dr. Ferrer BioPharma develop or market?

  We link 2 drug profile(s) where Dr. Ferrer BioPharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ferrer-internacional-s-a#company-drugs.

• What are the latest developments for Dr. Ferrer BioPharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Dr. Ferrer BioPharma focus on?

  Dr. Ferrer BioPharma focuses on Progressive supranuclear palsy (PSP), Amyotrophic Lateral Sclerosis based on our analysis of their pipeline programs and drug development activities.